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Purpose: To report the efﬁcacy of oral clopidogrel for treatment of chronic and recurrent central serous
chorioretinopathy (CSC).
Methods: This is a retrospective uncontrolled case series. Fourteen eyes in 14 patients with the clinical
and angiographic ﬁndings of chronic and recurrent CSC were enrolled. Clinical data including best-
corrected visual acuity (BCVA), durations of symptoms, central retinal thickness (CRT) and macular
volume measured on optical coherence tomography (OCT) were collected at baseline. Oral clopidogrel
75 mg daily was administrated at least for 2 weeks until the serous detachment resolved or no satis-
factory result was obtained. OCT was performed monthly until the end of follow-up in all patients.
Fluorescein angiography was repeated during the follow-up period in nine patients.
Results: There were eight eyes with chronic CSC and six with recurrent CSC. After clopidogrel treatment
for mean 8.07 weeks (range, 2e24 weeks), the BCVA improved or stabilized in 12 of 14 eyes (85.7%) at the
end of follow-up. Nine eyes (64.3%) attained a complete resolution of serous detachment, and four
(28.6%) had improvement in subretinal ﬂuid reabsorption on OCT. The CRT and macular volume were
signiﬁcantly decreased compared with baseline (234.14  62.46 mm vs. 355.64  108.05 mm, and
7.145  0.618 mL vs. 7.916  1.056 mL, respectively, p < 0.001). Seven eyes (77.78%) showed decreased
numbers of leaking point as well as decreased intensity of dye leakage on repeated ﬂuorescein angi-
ography and one eye (11.11%) had a complete resolution in previous dye leakage. Five eyes received
additional treatments (four eyes with laser photocoagulation and one eye with photodynamic therapy)
during or after the clopidogrel therapy. In the subgroup of patients without additional treatments, the
difference of CRT and macular volume was still statistically signiﬁcant.
Conclusion: Clopidogrel seems to be effective in the treatment of chronic CSC in this study. Its antith-
rombotic and anti-inﬂammatory actions may improve the choroidal congestion and facilitate the reab-
sorption of subretinal ﬂuid.
Copyright  2012, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Central serous chorioretinopathy (CSC) is characterized by the
development of a well-circumscribed, serous detachment of
neurosensory retina in the posterior pole. It often occurs in healthy
people, primarily in men, aged 25e45 years old.1 The commonlogy, Taipei Veterans General
17, Taiwan.
.
e Ophthalmologic Society of Taiwpresented symptoms are decreased visual acuity (VA), vision
dimness, micropsia, metamorphopsia, paracentral scotoma, or
increasing hyperopia. It is known that people with elevated corti-
costeroid level, whether endogenous or external administration,2
type A personality,3 pregnancy,4 and uncontrolled hypertension5
are at systemic risk of developing CSC.
By using indocyanine green angiography and optical coherent
tomography (OCT) on the choroid, studies have shown delayed
arterial ﬁlling and congestion of the choroidal veins as well as
increased choroidal thickness in patients with CSC, providing
evidence that increased hydrostatic pressure may play signiﬁcantan. Published by Elsevier Taiwan LLC. All rights reserved.
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have as their denominator increased hypercoagulability and
increased platelet aggregation. This chain of events appears to be
linked to an increase in plasminogen activator inhibitor 1 (PAI-1).8,9
Clopidogrel, a thienopyridine derivative, inhibits platelet acti-
vation and aggregation by inhibiting adenosine diphosphate (ADP).
It exerts its antiplatelet effect by forming an inactivating disulﬁde
bond with platelet P2Y12 ADP receptor.10 It also can lower plasma
PAI-1 levels.11 Therefore clopidogrel has provided beneﬁt in the
treatment and prevention of atherothrombogenesis.
Dr Ando presented a poster of a case series of CSC patients
taking clopidogrel treatment with good results in the Gonin club
meeting, Kyoto, 2011. His report inspired us to do this short-term
trial. We hypothesized that the antiplatelet and antithrombotic
effects of clopidogrel may improve the vessel congestion of choroid,
which directs to the pathogenesis of CSC, and may becomes a new
strategy of treatment for CSC.
2. Methods
2.1. Participants
This study followed the tenets of the Declaration of Helsinki. The
institutional review board at the hospital approved the observation
for the functional and image change of eyes with CSC and the
retrospective analysis performed in this study. Consecutive patients
with chronic or recurrent CSC who agreed to take clopidogrel were
examined and enrolled from November 2010 to December 2011 at
Taipei Veterans General Hospital, Taipei, Taiwan, a tertiary referral
center. The chronic CSC was deﬁned as ﬁndings of focal or multi-
focal, irregularly distributed or widespread retinal pigment
epithelium change with varying degrees of dye leakage on ﬂuo-
rescein angiography (FA) and a history of persisted symptoms for at
least three months. Recurrent CSC included ﬁndings of minimal
retinal pigment epithelium change on FA and a smokestack or ink
blot leakage pattern consistent with acute CSC but with an
apparent history of recurrence. Patients with concurrent eye
diseases such as intraocular inﬂammation, exudative or neo-
vascularized maculopathy, diabetic retinopathy, or preretinal
membrane were excluded.
2.2. Study designs
All patients initially underwent comprehensive ophthalmologic
examinations, including best-corrected visual acuity (BCVA)
measurement using a Snellen chart, slit-lamp biomicroscopy,
indirect ophthalmoscopy, fundus biomicroscopy with a contact
lens, FA (Canon CF-60 fundus camera; Canon Inc., Tokyo, Japan),
and spectral domain optical coherence tomography (RTVue-100
SD-OCT; Optovue Inc., Fremont, CA, USA). In cases where the
diagnosis was questionable, indocyanine green angiohraphy was
also performed.
SD-OCT examination was performed using cross-line protocol
and EMM5 macular mapping scan centered on the fovea in both
eyes for every patient. The EMM5 scan using a grid-like scanning
patternwith an outer 6 mm 6 mm area with 13 horizontal and 13
vertical scans of 0.5 mm interval and an inner 4 mm  4 mm area
with 8 horizontal and vertical scans to generate an en-face image of
the macula. Then the average central foveal ﬁeld of 1000-mm area
retinal thickness (central retinal thickness, CRT) was measured
using a full retina thickness map protocol and the macular volume
was determined using volumetric analysis function of the RTVue
built-in software.
Clinical data collected at the baseline were BCVA, age, sex, lat-
erality, durations of positive symptoms, and notable systemicdiseases. Type of CSC (chronic or recurrent) was investigated
according to the pattern of dye leakage on FA. CRT as well as
macular volume on OCT was also measured. Area of serous
detachment wasmeasured on color photography andwas classiﬁed
as <1 disc area (DA), 1e2 DA, and >2 DA, respectively. Oral clopi-
dogrel 75 mg daily was given to the patients if there were no
contraindications, such as active bleeding, severe liver impairment,
or hypersensitivity. The duration of treatment was at least 2 weeks.
Cessation of clopidogrel therapy was achieved when the subretinal
ﬂuid (SRF) resolved, there was no response after 2 months treat-
ment, or intolerable adverse systemic effects were noted.
Ophthalmologic examinations, including BCVA measurement and
OCT, were performed monthly throughout the period of study. FA
was repeated during the follow-up period in all participants except
ﬁve patients. Additional treatments for the CSC, including focal
photocoagulation and photodynamic therapy (PDT), during or after
the clopidogrel therapy were performed if symptoms persisted or
patient had occupational needs. The focal photocoagulation was
conducted following the conventional guidelines,1 and the verte-
porﬁn PDT was conducted with reduced ﬂuence (300 mW/cm2)
treatment parameters.12
2.3. Statistical analysis
Statistical analysis was performed using SPSS software to verify
the efﬁcacy of clopidogrel therapy. The Snellen visual acuity was
converted to the logarithm of the minimal angle of resolution
(logMAR) for analysis. The paired Student’s t test was used to
compare BCVA values, CRT and macular volume before and after
clopidogrel treatment. The ManneWhitney U test was conducted
to analyze whether a signiﬁcant difference was present among the
variables between chronic and recurrent CSC groups. A p-value of
0.05 was accepted as statistically signiﬁcant.
3. Results
Fourteen eyes of 14 patients were recruited in this study,
including 9 males and 5 females. The mean age of patients was
45.14  2.27 years (range, 32e58 years). On initial examination,
eight eyes showed chronic CSC and six were recurrent CSC. The
duration of symptoms before clopidogrel therapy ranged 0.5e17
months (mean, 5.25 months). The most common associated
systemic disease was hypertension (3 cases, 21.4%). Cases 3 and 11
received oral serratiopeptidase (Danzen; Takeda Inc., Osaka, Japan)
for 2 weeks and 4 weeks respectively before enrollment. Case 13
had an intravitreal injection with an unknown medication in
another hospital before starting clopidogrel therapy. The demo-
graphic and clinical data of all patients before and after the treat-
ment are shown in Table 1.
At baseline, the mean logMAR VA was 0.304  0.312, mean CRT
on OCT was 355.64  108.05 mm, and mean macular volume
measured on OCT was 7.916  1.056 mL. After an average of 8.07
weeks for clopidogrel treatment (range, 2e24 weeks, median 8
weeks), the BCVA improved (2 lines in Snellen) or stabilized (loss
1 line in Snellen) in 12 of 14 eyes (85.7%) at the end of follow-up.
All patients but Case 5 had a complete resolution of SRF (9 eyes,
64.3%) or improvement in SRF reabsorption (4 eyes, 28.6%) on OCT.
Repeated FA was available in nine patients during or after the clo-
pidogrel therapy, and seven cases (77.78%) showed decreased
numbers of leaking point as well as decreased intensity of dye
leakage on FA and one case (11.11%) had a complete resolution in
previous dye leakage (Table 1). At the ﬁnal visit, the mean logMAR
VA was 0.235  0.305, mean CRT was 234.14  62.46 mm, and the
macular volume was 7.145  0.618 mL. Signiﬁcant difference
between baseline and ﬁnal visit was found for CRT and macular
Table 1
Demographic and clinical data before and after clopidogrel treatment in 14 patients with central serous chorioretinopathy.
Patient No./
Sex/Age (y)
Duration of
symptoms before
clopidogrel (mo)
Type of CSC/Laterality
1: Chronic 2: Recurrent
Area of
SRF in color
photography
BCVA (logMAR) Macular volume (mL) CRT on OCT (mm)
Initial Final Initial Final Initial Final
1/F/56 3 1/OD <1 DA 0 (distortion) 0.155
(no distortion)
9.57 7.88 486 376
2/F/32 7.5 2/OD >2 DA 0.097 0 7.912 7.002 383 186
3/M/49 11 2/OD 1e2 DA 0.046 0 6.552 5.68 271 215
4/M/42 2.5 2/OD <1 DA 0.046 (dim) 0 7.961 7.028 416 204
5/M/43 4.5 1/OS <1 DA 0.523 0.699 7.423 7.364 186 196
6/M/47 4 1/OS <1 DA 1.0 1.0 6.852 6.6 191 155
7/F/54 1 2/OS 1e2 DA 0.222 0.222 7.136 6.87 332 255
8/M/42 1 2/OD 1e2 DA 0 (dim) 0 10.36 7.73 503 340
9/M/58 3 1/OS 1e2 DA 0.301 0.097 8.02 7.22 503 233
10/M/34 4 1/OD <1 DA 0.222 0.046 7.73 6.94 290 205
11/F/46 17 1/OD <1 DA 0.301
(micropsia)
0.155 7.28 7.13 322 286
12/M/55 3.5 1/OS <1 DA 0.699 0.523 7.2 7.14 286 182
13/M/36 0.5 2/OS 1e2 DA 0.699 0.398 7.92 7.1 341 199
14/F/38 12 1/OD 1e2 DA 0.097 0 8.91 8.34 469 246
Mean (SD) 5.32 (4.84) 0.304 (0.312) 0.235 (0.311) 7.916 (1.056) 7.145* (0.618) 355.64 (108.05) 234.14* (62.46)
Patient No./
Sex/Age (y)
Final fovea
contour in OCT
FA after treatment Follow-up
duration after
clopidogrel (mo)
Duration of
clopidogrel
treatment (wk)
Additional treatment
during or after
clopidogrel use
Associated systemic
diseases and
concurrent medications
1/F/56 Improved Improved 4 16 None Cervical CA s/p OP
2/F/32 Flat Improved 5 8 None ____
3/M/49 Flat No leakage 5.5 2 None ____
4/M/42 Flat Improved 7.5 8 Focal PC, 1 week later after clopidogrel ____
5/M/43 No response Persisted 4 4 Focal PC, 18 days later after clopidogrel Gout, HBV
6/M/47 Flat N/A 1.5 6 None ____
7/F/54 Flat N/A 1 4 None HTN
8/M/42 Improved N/A 2 4 None ____
9/M/58 Flat Improved 8 10 PDT, 16 days after clopidogrel ____
10/M/34 Flat N/A 1.5 5 None HTN
11/F/46 Improved Improved 3 8 Focal PC during clopidogrel ____
12/M/55 Flat Improved 3.5 8 None HTN, PV with aspirin 100 mg QD
13/M/36 Improved Improved 6 24 Focal PC during clopidogrel Plant hormone supplement
14/F/38 Flat N/A 2.5 6 None ____
Mean (SD) 3.93 (2.23) 8.07 (1.53)
*p  0.05 in paired t test.
BCVA ¼ best-corrected visual acuity; CA ¼ cancer; CRT ¼ central retinal thickness; DA ¼ disc area; FA ¼ ﬂuorescein angiography; HBV ¼ hepatitis B; HTN ¼ hypertension;
NA ¼ not available; OCT ¼ optical coherence tomography; OP ¼ operation; PC ¼ photocoagulation; PDT ¼ photodynamic therapy; PV ¼ polycythemia vera; SD ¼ standard
deviation; SRF ¼ subretinal ﬂuid.
Fig. 1. Scatterplot of visual acuity (expressed in Snellen equivalent) at baseline versus
ﬁnal visit in 14 eyes after clopidogrel treatment for central serous chorioretinopathy.
All points above the line imply improved ﬁnal visual acuity.
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with improvement in logMAR VA after clopidogrel therapy for CSC,
although the difference was not statistically signiﬁcant (p ¼ 0.075).
Mean follow-up duration was 3.93 months (range, 1e8 months).
Fig. 1 illustrates the gain in BCVA after clopidogrel treatment. The
mean CRT and macular volume at baseline and changes with
follow-up are summarized in Fig. 2.
In order to evaluatewhether clopidogrel treatment had different
efﬁcacy in chronic and recurrent CSC, the two groupswere analyzed
separately. There were no signiﬁcant differences in age, length of
clopidogrel therapy, baseline CRT and MV, or ﬁnal CRT and MV
between chronic and recurrent groups (Table 2). The average dura-
tion of symptoms was longer in chronic CSC but the difference did
not show statistical signiﬁcance (6.25 5.32months vs. 3.92 4.33
months, p¼ 0.169). In the eight patientswith chronic CSC,meanCRT
on OCT at baseline was 341.63  128.82 mm, and mean macular
volumewas 7.873 0.929 mL. After clopidogrel treatment, themean
CRT was 234.88  69.95 mm, and mean macular volume was
7.327 0.547 mL. Therewas a statistically signiﬁcant decrease in CRT
and macular volume (p ¼ 0.016 and p ¼ 0.027, respectively). In the
recurrent CSC group, similar results were shown, that is, clopidogrel
signiﬁcantly lowered the CRT (374.33  79.93 mm vs.
233.17 57.38 mm; p¼ 0.003) andmacular volume (7.9731.298 mL
vs. 6.902  0.670 mL; p ¼ 0.022). The treatment responses of both
Fig. 2. Graph showing the percentage change in central retinal thickness (CRT) and macular volume after clopidogrel treatment compared with baseline. Open circles with the
connecting solid line indicate the CRT, and solid triangles with connecting dashed line indicate the macular volume. The CRT and macular volume decreased at week 4 (75.2%, 93.9%
respectively) and week 8 (75.6%, 92.2%, respectively) after clopidogrel treatment. * Statistically signiﬁcant, p < 0.05.
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CRT or macular volume (p ¼ 0.95 and p ¼ 0.181, respectively). The
percentage of complete resolution of SRF showing on OCT was
similar (62.5% vs. 66.7%) in these two groups.
Four eyes (28.6%) underwent laser photocoagulation and one
eye (7.14%) underwent PDT for persisted symptoms or occupational
need during or after the clopidogrel therapy. In the subgroup of
patients without the above treatments for CSC, signiﬁcant differ-
ences between baseline and ﬁnal visit were still found for CRT
(367.50  112.13 mmvs. 243.13  78.75 mm; p ¼ 0.001) and macular
volume (8.209  1.270 mL vs. 7.313  0.600 mL; p ¼ 0.022). There
was no signiﬁcant association between length of clopidogrel
therapy and ﬁnal logMAR VA (Pearson’s coefﬁcient ¼ 0.076;
p ¼ 0.797). Five patients received clopidogrel therapy solely
without additional treatments in chronic CSC group. Four patients
(80%) had complete reabsorption of SRF and showed ﬂat foveal
contour on OCT at the ﬁnal visit. The CRT signiﬁcantly decreased
after clopidogrel therapy (344.40  127.94 mm vs.
232.80  86.73 mm; p ¼ 0.022, data not shown). Meanwhile, four
patients in the recurrent CSC group used clopidogrel as the only
treatment. Three out of four (75%) showed complete reabsorption
of SRF with ﬂat fovea on OCT.
A representative example (Case 14; Fig. 3) had persistent serous
detachment for 12 months. The resolution of serous detachment
and absorption of SRF was clearly shown on OCT after adminis-
tration of clopidogrel for 6 weeks.
One patient (Case 12) had systemic disease of polycythemia
vera. He used oral aspirin 100 mg daily for 2 months before beingTable 2
Comparison between chronic and recurrent central serous chorioretinopathy (CSC) grou
Chronic C
No. of patients 8
Age (mean  SD, y) 47.13  8
Duration of symptoms (mo) 6.25  5.3
Length of clopidogrel therapy (wk) 7.88  3.8
Baseline CRT on OCT (mean  SD, mm) 341.63 
Baseline MV on OCT (mean  SD, mL) 7.873  0
Final CRT on OCT (mean  SD, mm) 234.88 
Final MV on OCT (mean  SD, mm) 7.327  0
Patients with additional treatments (laser & PDT) 3
Percentage of complete resolution of SRF on OCT 62.5% (5/8
CRT ¼ central retinal thickness; MV ¼ macular volume; OCT ¼ optical coherence tomogenrolled in this study. Concomitant aspirin and clopidogrel were
given during the study period. At the initial examination, serous
detachment and discrete dye leakage observed on FA were found
even under aspirin use (Fig. 4A). However, the resolution of serous
detachment was noted after administration of clopidogrel for 8
weeks. In addition, intensity of dye leakage was also decreased
(Fig. 4B).
At the end of follow-up, there were no manifested systemic or
ocular side effects in all patients.
4. Discussion
The pathogenesis of CSC is not completely understood. Because
there has been no deﬁnite objective method for estimating the
chronicity of CSC, the classiﬁcations of acute, chronic, and recurrent
CSC are mainly based on arbitrary deﬁnitions.13 Although the
characteristics and presentations of chronic and recurrent CSC are
different, they may share similar pathophysiology to a certain
extent. Our results showed that oral clopidogrel might be helpful in
management of both chronic and recurrent CSC. It could signiﬁ-
cantly decrease the CRTandmacular volume as well as facilitate the
resolution of serous detachment. Indeed, the parameters and
treatment efﬁcacy analyzed in both groups are comparable and do
not show signiﬁcant differences. All but one patient had an
improvement in SRF reabsorption on OCT, and 77.78% showed
decreased ﬂuorescein leakage on repeated FA. In addition, stabili-
zation or improvement of VA was achieved in 85.7% of patients.
May be due to chronic and recurrent CSC being the same disease inps.
SC Recurrent CSC p
6
.73 42.50  8.01 0.332
2 3.92  4.33 0.169
0 8.33  8.04 0.558
128.82 374.33  79.93 0.514
.929 7.973  1.298 1.000
69.95 233.17  57.38 0.95
.547 6.902  0.670 0.181
2
) 66.6% (4/6)
raphy; PDT ¼ photodynamic therapy; SD ¼ standard deviation.
Fig. 3. The course of serous detachment was shown on optical coherence tomography in Case 14. (A) The serous detachment was prominent in chronic active central serous
chorioretinopathy. (B) After 6 weeks of clopidogrel treatment, the subretinal ﬂuid was completely absorbed and the central retinal thickness was also decreased. (C) One month
after the end of treatment, the foveal contour was still ﬂat and no evidence of recurrence was found.
S.-Y. Lee et al. / Taiwan Journal of Ophthalmology 3 (2013) 14e1918nature, but present in different temporal stage, so they show the
similar response to clopidogrel treatment.
Clopidogrel inhibits ADP-induced platelet activation and aggre-
gation. Its antithrombotic action has been well established and it is
widely used in prevention and treatment of acute coronary
syndrome and other ischemic events. It is found that clopidogrel can
reduce the expression of platelet surface P-selectin and attenuate
the release of inﬂammatory makers such as tumor necrosis factor-
a and C-reactive protein.14,15 In addition, clopidogrel shows an
inhibitory effect on plasma PAI-1 level, which indicates that it has
noneplatelet-related effect on soluble modulators of thrombosis
and inﬂammation.11 However, aspirin had no such effect and this
might explain the improved absorption of SRF after adding clopi-
dogrel to aspirin in our case 12. We supposed that the antith-
rombotic and anti-inﬂammatory actions of clopidogrel contribute to
improve the hypercoagulability of choroid due to venous congestion
and inﬂammation, enhance the microvasculature of chorioca-
pillaris, and break the vicious cycle that leads to CSC.
Caccavale et al found that treatment with low dose aspirin
(100 mg/day) results in more rapid visual recovery with fewer
recurrences in patients with CSC. Of 113 eyes, 98 (86.7%) had remis-
sion of serous detachment on OCTafter administration of aspirin.8 InFig. 4. Fluorescein angiography and optical coherence tomography ﬁndings in Case 12 with
months and chronic central serous chorioretinopathy was demonstrated on ﬂuorescein angio
of microthrombosis events. (B) Concomitant clopidogrel 75 mg was administrated for chron
subretinal ﬂuid was absorbed as well.our short-term study, 13 out of 14 eyes (92.8%) had an improvement
in SRF absorption after clopidogrel treatment. It seemed that clopi-
dogrel is at least as effective as aspirin in resolution of CSC, especially
in patients with hypercoagulability disease (Case 12).
There was no statistically signiﬁcant difference in BCVA at the
initial and ﬁnal visits. This result may be partly explained by the fact
that some patients presented with metamorphopsia, micropsia, or
dim vision rather than decreased visual acuity. Moreover, in the
retrospective analysis of 157 cases of CSC, Gilbert et al found that
the range of visual acuity was variable evenwith similar-appearing
macular detachments. After long-term follow-up, there was no net
change in visual acuity if initial visual acuity was 20/30 in both
laser-treated and untreated group.16 Most patients attained favor-
able visual outcome after clopidogrel treatment in our study. Two
patients (Cases 5 and 6) remained with poor vision (Snellen visual
acuity 20/100) at the end of study. Foveal atrophy was noted on
OCT in both patients and discontinuity of inner segment and outer
segment of photoreceptor was found in one patient (Case 6). We
postulate that the SRF under retina persisted for longer period and
resulted in somehow irreversible damage to the photoreceptors.
These changes associated with permanent visual impairment in
chronic CSC are in agreement with ﬁndings in previous studies.17,18polycythemia vera. (A) Before clopidogrel treatment, the symptoms persisted for 3.5
graphy. At that time, the patient was prescribed aspirin 100 mg daily for the prevention
ic central serous chorioretinopathy. After 8 weeks, the dye leakage was improved and
S.-Y. Lee et al. / Taiwan Journal of Ophthalmology 3 (2013) 14e19 19Five patients had additional treatment (laser PC or PDT) during or
after the clopidogrel treatment course. Most of these patients asked
for additional treatment due to occupational needs, although the
volume of SRF much decreased after the clopidogrel therapy.
Nevertheless, SRF reabsorption and disease regression in most
patients are achievedbyclopidogrel use solely. Therewasonepatient
(Case 11) who had partial response after 2 months of clopidogrel
treatment. Thispatienthad takenplanthormoneextract for climactic
symptoms for some time. This hormone, genistein, increased the
serum levels of corticosterone in an animal study,19 which probably
explains her unfavorable response. One patient (Case 5) ceased clo-
pidogrel due to epigastralgia and dizziness after 4weeks. In contrast,
of the other nine patientswhodid not receive any laser or PDT, seven
(77.7%) had complete absorption of SRF and showed ﬂat fovea. FAG
also showeddecreaseddye leakage. Therefore, regardless ofwhether
patients received additional treatment or not, nearly 80% (4/5 in the
lasergroupand77.7% in thenontreatmentgroup)of thepatientswho
received clopidogrel therapy had improvement in leakage.
There are several limitations in our study. The retrospective
nature may lower the precision and conﬁdence of our ﬁndings.
Further shortcomings include the small sample size, short follow-up,
and absence of control groups. There is no comparison between the
treatmenteffectsof clopidogrel andthenatural courseof chronicCSC.
In addition, the enrollment of patients with concurrent additional
treatments may result in some bias. Additional treatments (laser PC
and PDT) during the clopidogrel therapy may somewhat contribute
to the reabsorption of SRF and become confounding factors in the
data analysis. Further investigations and more evidence are needed
before clopidogrel can be recommended in clinical practice.
In conclusion, clopidogrel seems effective and may be a new
strategy for treatment of chronic CSC. The antithrombotic and anti-
inﬂammation actions of clopidogrel may decrease choroidal
congestion and show promising effects in SRF reabsorption and
resolution of disease. Further studies will be needed to evaluate the
dosage and duration of administration of clopidogrel.References
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